Side-by-side · Research reference

LivagenvsPTD-DBM

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/32 cited

BAnimal-StrongHUMAN-REVIEWED10/40 cited

Livagen

Khavinson Bioregulator · Hepatoprotective Tetrapeptide

50%Dipeptidase inhibitionTimofeeva 2005

Oral / SQRoutes tested

LiverTarget tissueKhavinson 2001

Oral or SQ · Tissue-specific to liver

PTD-DBM

Wnt Pathway Activator · Fusion Peptide

Topical / SQAdministrationLee 2023 Ryu 2023

Animal-onlyEvidence level

Wnt/β-cateninPrimary pathway

Topical / SQ · Study-dependent

01Mechanism of Action

Parameter

Livagen

PTD-DBM

Primary target

Hepatocyte protein synthesis machineryBrodskiĭ 2001

CXXC5–Dishevelled protein-protein interaction

Pathway

Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001 Khavinson 2001

Inhibit CXXC5 binding to Dishevelled → Release Wnt/β-catenin pathway inhibitionLee 2015 Ryu 2023

Downstream effect

Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes

Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation

Feedback intact?

—

Not applicable — pathway derepression rather than receptor agonism

Origin

Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)

Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5

Antibody development

—

02Dosage Protocols

Parameter

Livagen

PTD-DBM

Animal dose (oral)

Not specified in abstracts; 2-week administration protocolTimofeeva 2005

Per os administration in rats.

—

Duration (experimental)

2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005 Brodskiĭ 2001

—

Route

Oral or subcutaneous

Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005

—

Evidence basis

Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005 Brodskiĭ 2001 Khavinson 2002

Animal models only (mice)

Human data

None in provided literature

—

Wound healing protocol

—

Hydrogel patch delivery (concentration not disclosed)

Pyrogallol-HA patch, murine model.

Hair regeneration protocol

—

Topical application (exact dose not disclosed)

Wound-induced hair neogenesis model, mice.

Co-administration

—

Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023

Combined treatment maximized scar reduction.

Human translation

—

No published human studies

04Side Effects & Safety

Parameter

Livagen

PTD-DBM

Reported adverse effects

None documented in animal studies

—

Human safety data

No human trials in provided literature

—

Peptide hydrolysis

Weakly hydrolyzed; minimal breakdown by intestinal enzymesTimofeeva 2005

—

Reported adverse events

—

None reported in animal studies

Wnt pathway activation risks

—

Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis

Long-term safety

—

Unknown — no chronic dosing or human data

Delivery vehicle effects

—

HA-PG hydrogel well-tolerated in mice; human translation pending

Absolute Contraindications

Livagen

—

PTD-DBM

·Active malignancy (Wnt pathway involvement in tumorigenesis)
·Pregnancy / lactation (no safety data)

Relative Contraindications

Livagen

—

PTD-DBM

·History of Wnt-driven tumors
·Skin lesions with uncertain malignant potential

05Administration Protocol

Parameter

Livagen

PTD-DBM

1. Route selection

Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005 Khavinson 2001

Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023

2. Timing

No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005

Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023

3. Age-dependent response

Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005

PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023

4. Storage & Handling

—

Not disclosed in available literature. Peptide stability and storage conditions not published.